In December 2020, Lira.ltd had the pleasure to announce that their client Novus Diagnostics Ltd. (SepTec) was the only Irish company to be awarded a €2.4m grant and offered a €5m equity investment in the most competitive EICAccelerator call ever. Now, Novus Diagnostics Ltd. is sharing valuable insights on the programme and what it takes …
The only Irish company to be awarded funding from this round of the European Innovation Council (EIC) Accelerator pilot, DCU-based Novus Diagnostics has been working in collaboration with two Dublin hospitals on validating the SepTec diagnostic device. The award is divided into €2.4m grant and €5m equity financing. https://www.irishtimes.com/business/health-pharma/novus-diagnostics-gets-2-4m-grant-for-rapid-sepsis-test-1.
SepTec was chosen as one of the 50 startups to join the Accelerator program. This year was extremely competitive, with only a 3% acceptance rate. MedTech Innovator evaluated the pitches of 190 candidates out of more than 1,000 applications from 45 countries and 48 U.S. states. https://medtechinnovator.org/medtech-innovator-announces-top-50-medtech-startups-selected-for-annual-showcase-and-accelerator/
SepTec was one of the Ninety-six start-ups from across Europe have been selected to take part in the annual EIT Health Headstart programme. We will have access to mentoring and business support, and financial support of up to €50,000, and will make valuable contacts within the health innovation ecosystem via EIT Health’s vast network. https://eithealth.eu/news-article/eit-health-announces-start-ups-selected-for-2020-headstart-programme/